Q&A – 2cureX general
2cureX is happy to receive a number of questions and comments from our present and from potential future shareholders.
With the present Questions & Answers (Q&A) section, we would like to make these questions and their answers publicly available. Additional questions/comments should be mailed to info@2cureX.com.
Posted on 2020-07-08
2cureX decided to raise funds now as we see a huge interest from customers for functional precision medicine into general hospital practice. 2cureX is strongly positioned for this, through its IP and Clinical Program, the company wants to capitalize on this by bringing IndiTreat to a broader set of markets than first anticipated as well as expanding into new cancer entities beyond Colorectal Cancer such as Pancreatic and Ovarian Cancer. As part of our VISION to become a leader in functional precision medicine, Automation of the IndiTreat test is a key component to make the test broadly available in multiple markets. Automation will allow for decentralization of the IndiTreat test and open for an attractive earning model.
Posted on 2020-07-07
For 2cureX the ambition to capitalize on the market opportunity led us to a preference for a Directed Issue to secure funds in a time- and cost-effective manner for the company. Beyond the increase of capital, the process helps to diversify our investor base and investor dynamics. As part of the directed rights issue it has been very important to ensure that our current shareholders would benefit from this process through the offering of warrants. 2cureX therefore offers its present shareholders warrants, free of charge, allowing to buy shares nine months from now at a discounted price.
Posted on 2019-12-18
2cureX is a commercial market leader focused on the clinical application of 3D drug-response testing of cancer patients. 2cureX builds on an experience with the technology in more than 1000 patients and is currently engaged in two Multinational Clinical Trials that will further strengthen the IndiTreat® competitive profile. With a CE-mark filing in 2018 and strong clinical evidence, 2cureX is aiming to be the leading company within functional drug-response testing.
Posted on 2019-08-26
3D drug-response testing is getting traction in Academia, supporting the value of the technology to identify Individual treatment strategies for cancer patients. 2cureX considers the increased interest by researchers for the use of 3D-cell cultures in cancer therapy design a market driver that will greatly support the commercial success of IndiTreat®.
Posted on 2018-11-11
2cureX has a strong patent portfolio on the method of applying 3D micro-tumors to the design of cancer treatment for the individual patient. The initial generation of 3D micro-tumors from patient tissue is not protected and is conducted by several academic researchers. The more clinical information they create the better it is for 2cureX.
Posted on 2018-08-07
Thank you for pointing out this issue to our attention. We have been in contact with Nordnet and our news distributor (Cision). It turns out that there has been an error in the distribution algorithm. This is very unfortunate. The error is now corrected. So, in the future, you will see the important press releases from 2cureX on Nordnet’s website.
Posted on 2018-05-12
We were very successful with our EU application and received EURO 3 Mill in funding. The funds will be used to support our clinical studies and commercialization of the IndiTreat® test. The funds will directly support the business plan of 2cureX.
Posted on 2018-03-14
None of the mentioned competitors are running clinical trials in colon cancer.
Please contact 2cureX for more information